Close Menu

sickle cell anemia

NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.

And Then for All

NIH Director Francis Collins describes at Forbes how the agency is working with the Bill & Melinda Gates Foundation to develop gene-based treatments for sickle cell disease and HIV for sub-Saharan Africa.

Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

Treatment So Far

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Bound for Home

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

The California startup is about to launch its first product, a noninvasive prenatal screening test for recessive single-gene disorders called Unity.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.